RIRS versus mPCNL for single renal stone of 2–3 cm: clinical outcome and cost-effective analysis in Chinese medical settingJiahua Pan, Yong Huang, Lei Xia et al.|Urolithiasis|2012Cited by 107
Recent Advances of Emerging Spleen‐Targeting Nanovaccines for ImmunotherapyXuanyi He, Xiangzhao Ai, Jing Wang et al.|Advanced Healthcare Materials|2023Cited by 42